U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Ravulizumab (Ultomiris): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 1 month of age and older with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy [Internet].

Ravulizumab (Ultomiris): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 1 month of age and older with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...